US Expansion Onyx Scientific is actively expanding its commercial operations in the United States with a dedicated Business Development Manager for North America, signaling a strong sales growth opportunity and potential for new CRO/CDMO partnerships in the US market.

UK Sunderland Growth Recent facility expansion in Sunderland, UK indicates capacity and capability growth in Europe, presenting cross-sell opportunities for European pharma clients seeking scalable small molecule API CDMO support and improved tech transfer.

Global Licensed Sites MHRA and FDA licensed sites in the UK and India enable compliant, international manufacturing and supply chain resilience, appealing to clients needing cross-border production, accelerated transfer, and risk mitigation for global programs.

Mid-market Focus With 51–200 employees and $10–$25M revenue, Onyx sits in the mid-market CDMO space, offering flexible scale-up, early-stage chemistry, and Phase I–III support—ideal for biotech firms transitioning from discovery to GMP manufacturing.

Leadership & Outreach Strategic hires in North America and a track record as a preferred partner to top pharmaceutical firms suggest a proactive business development approach, creating upside for targeted outreach to large pharma and mid-cap biopharma seeking reliable CDMO collaboration.